• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过miRNA和mRNA的加权共表达网络分析表明,miR-363-5p作为肝细胞癌潜在的预后标志物。

miR-363-5p as potential prognostic marker for hepatocellular carcinoma indicated by weighted co-expression network analysis of miRNAs and mRNA.

作者信息

Zhang Jun, Fan Jia, Zhou Chongming, Qi Yanyu

机构信息

Department of Oncology, The third people's hospital of Chengdu, Chengdu, 610031, China.

出版信息

BMC Gastroenterol. 2017 Jun 20;17(1):81. doi: 10.1186/s12876-017-0637-2.

DOI:10.1186/s12876-017-0637-2
PMID:28637446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5480191/
Abstract

BACKGROUND

This study aimed to investigate potential miRNAs and genes associated with the prognosis of hepatocellular carcinoma (HCC).

METHODS

Weighted co-expression network analysis was utilized to analyze the mRNA and miRNA sequencing data of HCC from TCGA (The Cancer Genome Atlas) database. Significant network modules were identified, and then functions of genes in the gene network modules and target genes of miRNAs in the miRNA network modules were explored. Additionally, correlations between network modules and prognostic factors of HCC were analyzed.

RESULTS

In total, 10 mRNA network modules were identified, three of which were significantly related to tumor stage, NAFLD (non-alcoholic fatty liver disease) and patient age. Four miRNA network modules were identified, of which one was associated with tumor stage. Targets of hsa-miR-363-5p were found distributed in the gene network modules, such as RGPD5, RGPD6, ZNF445 and ZNF780B. Kaplan-Meier test revealed that low expression of hsa-miR-363-5p was associated with better overall survival of HCC patients.

CONCLUSION

hsa-miR-363-5p may be a potential prognostic marker for HCC.

摘要

背景

本研究旨在探究与肝细胞癌(HCC)预后相关的潜在微小RNA(miRNA)和基因。

方法

利用加权共表达网络分析来分析来自癌症基因组图谱(TCGA)数据库的HCC的mRNA和miRNA测序数据。识别出显著的网络模块,然后探究基因网络模块中的基因功能以及miRNA网络模块中miRNA的靶基因。此外,分析网络模块与HCC预后因素之间的相关性。

结果

总共识别出10个mRNA网络模块,其中3个与肿瘤分期、非酒精性脂肪性肝病(NAFLD)和患者年龄显著相关。识别出4个miRNA网络模块,其中1个与肿瘤分期相关。发现hsa-miR-363-5p的靶基因分布在基因网络模块中,如RGPD5、RGPD6、ZNF445和ZNF780B。Kaplan-Meier检验显示,hsa-miR-363-5p低表达与HCC患者更好的总生存期相关。

结论

hsa-miR-363-5p可能是HCC的一个潜在预后标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/826cecb8953b/12876_2017_637_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/ac2035ee2484/12876_2017_637_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/4148a8ace1c8/12876_2017_637_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/c7894437f2f1/12876_2017_637_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/3ffbd5c0ab37/12876_2017_637_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/826cecb8953b/12876_2017_637_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/ac2035ee2484/12876_2017_637_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/4148a8ace1c8/12876_2017_637_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/c7894437f2f1/12876_2017_637_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/3ffbd5c0ab37/12876_2017_637_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98b9/5480191/826cecb8953b/12876_2017_637_Fig5_HTML.jpg

相似文献

1
miR-363-5p as potential prognostic marker for hepatocellular carcinoma indicated by weighted co-expression network analysis of miRNAs and mRNA.通过miRNA和mRNA的加权共表达网络分析表明,miR-363-5p作为肝细胞癌潜在的预后标志物。
BMC Gastroenterol. 2017 Jun 20;17(1):81. doi: 10.1186/s12876-017-0637-2.
2
Bioinformatics Analyses of Potential miRNA-mRNA Regulatory Axis in HBV-related Hepatocellular Carcinoma.基于生物信息学分析乙型肝炎病毒相关性肝细胞癌中潜在的 miRNA-mRNA 调控轴。
Int J Med Sci. 2021 Jan 1;18(2):335-346. doi: 10.7150/ijms.50126. eCollection 2021.
3
Genome-Wide Analysis of Prognostic lncRNAs, miRNAs, and mRNAs Forming a Competing Endogenous RNA Network in Hepatocellular Carcinoma.肝细胞癌中构成竞争性内源RNA网络的预后性长链非编码RNA、微小RNA和信使RNA的全基因组分析
Cell Physiol Biochem. 2018;48(5):1953-1967. doi: 10.1159/000492519. Epub 2018 Aug 9.
4
A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis.一种用于肝细胞癌诊断和预后的新型微小RNA表达特征。
Oncotarget. 2017 Jan 31;8(5):8775-8784. doi: 10.18632/oncotarget.14452.
5
A Seven-microRNA Expression Signature Predicts Survival in Hepatocellular Carcinoma.一种七微小RNA表达特征可预测肝细胞癌的生存率。
PLoS One. 2015 Jun 5;10(6):e0128628. doi: 10.1371/journal.pone.0128628. eCollection 2015.
6
[Identification of onco-miRNAs in hepatocellular carcinoma and analysis of their regulatory network].[肝细胞癌中癌基因miRNA的鉴定及其调控网络分析]
Nan Fang Yi Ke Da Xue Xue Bao. 2022 Jan 20;42(1):45-54. doi: 10.12122/j.issn.1673-4254.2022.01.05.
7
A P53-related microRNA model for predicting the prognosis of hepatocellular carcinoma patients.一个与 P53 相关的 microRNA 模型,用于预测肝癌患者的预后。
J Cell Physiol. 2020 Apr;235(4):3569-3578. doi: 10.1002/jcp.29245. Epub 2019 Sep 25.
8
Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles.基于 miRNA 表达谱鉴定肝癌的预后标志物。
Life Sci. 2019 Sep 1;232:116596. doi: 10.1016/j.lfs.2019.116596. Epub 2019 Jun 22.
9
Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance.肝细胞癌相关的微小RNA表达特征:综合生物信息学分析、实验验证及临床意义
Oncotarget. 2015 Sep 22;6(28):25093-108. doi: 10.18632/oncotarget.4437.
10
Candidate lncRNA-miRNA-mRNA network in predicting hepatocarcinogenesis with cirrhosis: an integrated bioinformatics analysis.候选 lncRNA-miRNA-mRNA 网络预测肝硬化肝癌发生:一项综合生物信息学分析。
J Cancer Res Clin Oncol. 2020 Jan;146(1):87-96. doi: 10.1007/s00432-019-03090-z. Epub 2019 Nov 22.

引用本文的文献

1
miR-363-5p regulates liver disease via the MAPK/ERK signaling pathway by targeting CPEB2 in chicken.在鸡中,miR-363-5p通过靶向CPEB2,经由丝裂原活化蛋白激酶/细胞外信号调节激酶(MAPK/ERK)信号通路调控肝脏疾病。
Poult Sci. 2025 Aug 6;104(10):105660. doi: 10.1016/j.psj.2025.105660.
2
The use of circulating miRNAs for the diagnosis, prognosis, and personalized treatment of MASLD.循环微小RNA在非酒精性脂肪性肝病的诊断、预后及个性化治疗中的应用
J Physiol Biochem. 2025 Jul 16. doi: 10.1007/s13105-025-01110-w.
3
lncRNA PITPNA-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by upregulating PDGFD.

本文引用的文献

1
Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.锌指蛋白ZBTB20是一种独立的预后标志物,通过抑制FoxO1促进人类肝细胞癌的肿瘤生长。
Oncotarget. 2016 Mar 22;7(12):14336-49. doi: 10.18632/oncotarget.7425.
2
Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.剪接调控因子 SLU7 通过致癌性 miR-17-92 簇表达来维持肝癌细胞和其他实体肿瘤的存活。
Oncogene. 2016 Sep 8;35(36):4719-29. doi: 10.1038/onc.2015.517. Epub 2016 Jan 25.
3
Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.
长链非编码 RNA PITPNA-AS1 通过上调 PDGFD 促进肝癌细胞增殖和转移。
Aging (Albany NY). 2023 Mar 2;15(10):4071-4083. doi: 10.18632/aging.204566.
4
Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD).系统生物学方法揭示了 COVID-19 和非酒精性脂肪性肝病 (NAFLD) 的共同分子基础。
Eur J Med Res. 2022 Nov 15;27(1):251. doi: 10.1186/s40001-022-00865-y.
5
During HCV DAA Therapy Plasma Mip1B, IP10, and miRNA Profile Are Distinctly Associated with Subsequent Diagnosis of Hepatocellular Carcinoma: A Pilot Study.丙型肝炎病毒直接抗病毒药物治疗期间,血浆Mip1B、IP10和微小RNA谱与随后肝细胞癌的诊断显著相关:一项初步研究。
Biology (Basel). 2022 Aug 25;11(9):1262. doi: 10.3390/biology11091262.
6
Bioinformatics Study Revealed Significance of Exosome Transcriptome in Hepatocellular Carcinoma Diagnosis.生物信息学研究揭示了外泌体转录组在肝细胞癌诊断中的意义。
Front Cell Dev Biol. 2022 Apr 27;10:813701. doi: 10.3389/fcell.2022.813701. eCollection 2022.
7
Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma.建立用于胶质瘤患者风险分层的免疫相关基因特征。
Comput Math Methods Med. 2021 Aug 27;2021:2191709. doi: 10.1155/2021/2191709. eCollection 2021.
8
lncRNA MCM3AP-AS1 promotes the development of oral squamous cell carcinoma by inhibiting miR-363-5p.长链非编码RNA MCM3AP-AS1通过抑制miR-363-5p促进口腔鳞状细胞癌的发展。
Exp Ther Med. 2020 Aug;20(2):978-984. doi: 10.3892/etm.2020.8738. Epub 2020 May 12.
9
MiR-363 suppresses cell migration, invasion, and epithelial-mesenchymal transition of osteosarcoma by binding to NOB1.miR-363 通过与 NOB1 结合抑制骨肉瘤细胞迁移、侵袭和上皮-间充质转化。
World J Surg Oncol. 2020 May 1;18(1):83. doi: 10.1186/s12957-020-01859-y.
10
Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-II in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma.维生素 K 缺乏或拮抗剂-II 诱导的 LHPP 相关 microRNAs 与蛋白联合检测在甲胎蛋白阴性肝细胞癌诊断中的临床价值。
J Clin Lab Anal. 2020 Feb;34(2):e23071. doi: 10.1002/jcla.23071. Epub 2019 Nov 6.
细胞命运决定因子Numb在肝细胞癌中的可变剪接
Hepatology. 2015 Oct;62(4):1122-31. doi: 10.1002/hep.27923. Epub 2015 Jul 3.
4
MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors.微小RNA-494是侵袭性人类肝细胞癌肿瘤中多种侵袭抑制性微小RNA的主要表观遗传调节因子,它通过靶向10-11易位甲基胞嘧啶双加氧酶1发挥作用。
Hepatology. 2015 Aug;62(2):466-80. doi: 10.1002/hep.27816. Epub 2015 May 6.
5
Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets.通过抑制多个靶点,微小RNA-101的全身递送在体内有效抑制肝细胞癌。
PLoS Genet. 2015 Feb 18;11(2):e1004873. doi: 10.1371/journal.pgen.1004873. eCollection 2015 Feb.
6
Identification of dysregulated microRNAs in triple-negative breast cancer (review).三阴性乳腺癌中失调 microRNAs 的鉴定(综述)。
Int J Oncol. 2015 Mar;46(3):927-32. doi: 10.3892/ijo.2015.2821. Epub 2015 Jan 8.
7
An investigation into anti-proliferative effects of microRNAs encoded by the miR-106a-363 cluster on human carcinoma cells and keratinocytes using microarray profiling of miRNA transcriptomes.采用 miRNA 转录组芯片分析研究 miR-106a-363 簇编码的 microRNAs 对人癌细胞和角质细胞的抗增殖作用。
Front Genet. 2014 Aug 25;5:246. doi: 10.3389/fgene.2014.00246. eCollection 2014.
8
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.微小RNA-425-3p可预测肝细胞癌患者对索拉非尼治疗的反应。
Liver Int. 2015 Mar;35(3):1077-86. doi: 10.1111/liv.12636. Epub 2014 Jul 21.
9
Growth inhibition of hepatocellular carcinoma tumor endothelial cells by miR-204-3p and underlying mechanism.miR-204-3p对肝癌肿瘤内皮细胞的生长抑制作用及其潜在机制
World J Gastroenterol. 2014 May 14;20(18):5493-504. doi: 10.3748/wjg.v20.i18.5493.
10
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.剪接因子 hnRNP A2 通过控制 A-Raf 的剪接激活肝癌发展中的 Ras-MAPK-ERK 通路。
RNA. 2014 Apr;20(4):505-15. doi: 10.1261/rna.042259.113. Epub 2014 Feb 26.